Gyre Therapeutics, Inc.
NASDAQ:GYREBiotechnology
+$0.00 today
- Market cap
- $475.02M
- Beta
- 4.92
- P/E (TTM)
- -88.3
- EPS (TTM)
- -$0.07
Volume 0.47M
Average 0.09M
GYRE Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Gyre Therapeutics, Inc.NASDAQ: GYRE
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income turns negative
Q1 FY2026 net income was -$8.69M, compared with $3.73M a year earlier. Trailing-twelve-month net income was -$3.58M. Over 3 fiscal years it compounded at +31.8% a year.
Context
- Net income amounted to 8.5% of revenue in FY2025, down 8.4 pp from a year earlier.
- Net income increased in 1 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 2 analysts of -$30.35M (-407.2%) for the fiscal year ending Dec 2026, a slowdown from the -44.8% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$8.69M+261.8% QoQ
- Last fiscal yearDec 2025
- $9.88M-44.8% YoY
- LTMMar 2026
- -$3.58M-140.0% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- 9.88M USD
- Year-over-year change
- -44.8%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 9.88M | -44.8% |
| FY2024 | 2024-12-31 | 17.9M | +120.9% |
| FY2023 | 2023-12-31 | (85.48M) | -2081.5% |
| FY2022 | 2022-12-31 | 4.31M | +104.9% |
| FY2021 | 2021-12-31 | (87.93M) | — |
Net Income vs competitors
How GYRE compares with its peers on the latest reported figures
- GYRE's LTM Mar 2026 net income of $3.58M is the smallest of the 4 companies compared; the peer median is $113.22M.
- Its year-over-year change of -140.0% is the lowest of 4, against a peer median of -41.9%.
- Net income amounts to 3.1% of revenue for GYRE, versus a peer median of 4571.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $342.56M | +319.3% | +88.7% | 4571.1% | |
| LTM Mar 2026 | $113.22M | -48.4% | +6.6% | — | |
| LTM Mar 2026 | $26.25M | -41.9% | -7.4% | — | |
| LTM Mar 2026 | $3.58M | -140.0% | +31.8% | 3.1% | |
AGMBAgomAb Therapeutics N.V. American Depositary Shares | — | — | — | — | — |
| Peer median (excluding GYRE) | $113.22M | -41.9% | +6.6% | 4571.1% | |
Competitors are the stored peer set for GYRE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (87.93M) | 4.31M | (85.48M) | 17.9M | 9.88M |
| Depreciation & Amortization | 290K | 1.13M | 1.11M | 1.59M | 2.48M |
| Deferred Income Tax | (3.89M) | (838K) | (1.16M) | (1M) | (1.11M) |
| Stock-Based Compensation | 3.41M | 13.37M | 7.28M | 831K | 7.16M |
| Change in Working Capital | 483K | (7.8M) | 7.46M | (15.69M) | (15.55M) |
| Accounts Receivables | 1.5M | (7.92M) | 1.3M | (9.29M) | (11.95M) |
| Inventory | 3.88M | (879K) | 1.75M | (2.14M) | (3.63M) |
| Accounts Payables | 500K | (112K) | 192K | (245K) | 13K |
| Other Working Capital | (5.39M) | 1.11M | 4.22M | (4.02M) | 17K |
| Other Non-Cash Items | 3.89M | 503K | 96.68M | (7.27M) | (1.85M) |
| Operating Cash Flow | (83.76M) | 10.68M | 25.89M | (3.64M) | 1.01M |
| Capital Expenditures | (839K) | (5M) | (8.59M) | (3.13M) | (1.19M) |
| Acquisitions (Net) | 0 | (1.33M) | 4.02M | (1.69M) | 30K |
| Purchases of Investments | 0 | (7.48M) | (15.74M) | (15.47M) | 0 |
| Sales of Investments | 49.03M | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | (13K) | 471K | (412K) | 686K |
| Investing Cash Flow | 48.19M | (13.81M) | (19.76M) | (19.88M) | (474K) |
| Debt Repayment | (6.7M) | 0 | 0 | 0 | 0 |
| Common Stock Issued | 49.55M | 0 | 0 | 773K | 25.87M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 6.7M | 0 | 0 | 1.33M | (1.49M) |
| Financing Cash Flow | 49.55M | 0 | 2.5M | 2.1M | 24.38M |
| Effect of Forex Changes | 0 | (1.89M) | (298K) | (273K) | 343K |
| Net Change in Cash | 13.99M | (5.03M) | 8.33M | (21.7M) | 25.26M |
| Free Cash Flow | (84.59M) | 5.68M | 17.31M | (6.77M) | (180K) |
Gyre Therapeutics, Inc.
NASDAQ:GYRE
Intrinsic Alpha fair value
Locked
Current Price
$4.34
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.